Avidity Biosciences secures $400 million in private placement

Published on 29 Feb 2024 on Investing.com

Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company specializing in RNA...

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of the 7 Best Performing Long Term Stocks in 2024. In this article, ...

Insider Monkey · via Yahoo Finance 26 Sep 2024

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, ...

Insider Monkey · via Yahoo Finance 24 Sep 2024

Key Insights The projected fair value for Avidity Biosciences is US$46.34 based on 2 Stage Free C...

Simply Wall St. · via Yahoo Finance 20 Jun 2024

President and CEO Sarah Boyce of Avidity Biosciences Inc (NASDAQ:RNA) sold 28,000 shares of the c...

GuruFocus.com via Yahoo Finance 4 Apr 2024

Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 sha...

GuruFocus.com via Yahoo Finance 15 Mar 2024

Shares of Bitdeer Technologies Group BTDR rose sharply during Monday’s session after the compan...

Benzinga 4 Mar 2024

Monday, Avidity Biosciences Inc RNA revealed new long-term AOC 1001 data from the MARINA open-lab...

Benzinga 4 Mar 2024

As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to i...

Benzinga 1 Mar 2024

Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company specializing in RNA...

Investing.com 29 Feb 2024

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zack...

Zacks via Yahoo Finance 28 Feb 2024